Clinical Trial Update: Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccines [Phase 1]

View source ↗

Summary

This clinical trial update reports the completion of a Phase 1 study evaluating the safety, reactogenicity and immunogenicity of GlaxoSmithKline's investigation…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• RSV vaccine (investigational)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Respiratory Syncytial Virus | Phase 1 | Status: COMPLETED